- Home
- HOLO vs NRXP Comparison
HOLO vs NRXP Comparison
Compare HOLO & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HOLO
- NRXP
- Stock Information
- Founded
- HOLO 2018
- NRXP 2015
- Country
- HOLO China
- NRXP United States
- Employees
- HOLO N/A
- NRXP N/A
- Industry
- HOLO Computer Software: Programming Data Processing
- NRXP Biotechnology: Pharmaceutical Preparations
- Sector
- HOLO Technology
- NRXP Health Care
- Exchange
- HOLO Nasdaq
- NRXP Nasdaq
- Market Cap
- HOLO 66.3M
- NRXP 58.5M
- IPO Year
- HOLO N/A
- NRXP N/A
- Fundamental
- Price
- HOLO $4.93
- NRXP $3.59
- Analyst Decision
- HOLO
- NRXP Strong Buy
- Analyst Count
- HOLO 0
- NRXP 5
- Target Price
- HOLO N/A
- NRXP $31.40
- AVG Volume (30 Days)
- HOLO 3.1M
- NRXP 424.3K
- Earning Date
- HOLO 01-01-0001
- NRXP 11-13-2025
- Dividend Yield
- HOLO N/A
- NRXP N/A
- EPS Growth
- HOLO N/A
- NRXP N/A
- EPS
- HOLO 13.81
- NRXP N/A
- Revenue
- HOLO $44,840,587.00
- NRXP N/A
- Revenue This Year
- HOLO N/A
- NRXP N/A
- Revenue Next Year
- HOLO N/A
- NRXP $395.09
- P/E Ratio
- HOLO $0.37
- NRXP N/A
- Revenue Growth
- HOLO 37.10
- NRXP N/A
- 52 Week Low
- HOLO $4.16
- NRXP $1.10
- 52 Week High
- HOLO $370.00
- NRXP $6.01
- Technical
- Relative Strength Index (RSI)
- HOLO 47.61
- NRXP 67.23
- Support Level
- HOLO $4.87
- NRXP $3.19
- Resistance Level
- HOLO $5.66
- NRXP $3.84
- Average True Range (ATR)
- HOLO 0.46
- NRXP 0.22
- MACD
- HOLO -0.02
- NRXP 0.05
- Stochastic Oscillator
- HOLO 7.55
- NRXP 69.90
About HOLO MicroCloud Hologram Inc.
MicroCloud Hologram Inc, through its subsidiaries, is mainly engaged in holographic Technology. It includes Holographic solutions and Holographic technology services. The company also provides holographic digital twin technology services for customers and has built a holographic digital twin technology resource library. Geographically company is operating in single segment, China.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.